Home > Insider Trading > Filing (0000903423-16-000925)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1583107	Theravance Biopharma Inc.	TBPH	Pharmaceutical Preparations (2834)	X0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1131399	Plc Glaxosmithkline	980 Great West Road Brentford, Middlesex, X0 TW8 9GS		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2016-03-14	1,301,015	$23,027,965.50	9,644,807	No	4	P	Indirect	By Corporation

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Corporation

Footnotes

Common stock purchased pursuant to the right of Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, under Sections 2.1(a) and 2.1(d)(ii) of the Governance Agreement by and between TheravanceBiopharma, Inc. (the "Issuer") and GGL dated as of March 3, 2014. Pursuant to Section 2.1(d)(ii), GGL has the right to purchase from the Issuer, on a quarterly basis, sufficient ordinary shares to maintain its ownership percentage in the Issuer taking into account the preceding quarter's option exercise and equity vesting activity. Pursuant to Section 2.1(a), the Issuer's Board of Directors may approve additional purchases of ordinary shares by GGL.
Ordinary Shares are held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person.